Warm Autoimmune Hemolytic Anemia with a Direct Antiglobulin Test Positive for C3 and Negative for IgG: A Case Study and Analytical Literature Review of Incidence and Severity

Amruth R. Palla¹, Farhad Khimani², and Michael D. Craig²

¹Department of Medicine, Integris Southwest Medical Center, Oklahoma City, OK. ²Section of Hematology and Oncology, Department of Medicine, Mary Babb Randolph Cancer Hospital, West Virginia University, WV.
Corresponding author email: dr_amruth@yahoo.com

Abstract: Polygenic IgG autoantibodies are implicated in majority of the cases of warm autoimmune hemolytic anemia (WAIHA). In some of these cases, complement (C3) proteins accompany the IgG antibodies. WAIHA mediated by C3 alone is relatively rare. We present an interesting case of WAIHA with a direct antiglobulin test (DAT) positive for C3 but negative for IgG in a 79-year-old woman and perform an analytical literature review of the incidence and severity of this clinical entity.

Keywords: autoimmune hemolytic anemia, complement C3, Coombs test
Introduction
Autoimmune hemolytic anemia (AIHA) is the anemia from hemolysis due to autoantibodies. Three different types of AIHA can be studied based on the behavior of the autoantibodies involved in the pathogenesis:1 (1) Warm AIHA, which is most commonly mediated through IgG autoantibodies (polygenic; commonly against the antigens of Rh system) that are most potent at temperatures $\geq 37 \, ^\circ C$, (2) Cold AIHA, which is generally mediated through C3 component of the complement that fix the complement to the RBCs partially at low temperatures ($\leq 30 \, ^\circ C$) and then complete the process at temperatures $\geq 37 \, ^\circ C$. Most of the cases of AIHA have no identifiable etiology and hence are termed idiopathic or primary AIHA. The few cases where an underlying cause is identified are termed secondary AIHA and could be associated with lympho-proliferative diseases (lymphoma, Chronic Lymphocytic Lymphoma (CLL)), infections (mycoplasma as in cold AIHA or syphilis as in PCH and various other viral infections, such as the herpes family, retrovirus, and hepatitis), drugs (penicillin and methyl dopa), and other miscellaneous causes (connective tissue diseases, thyroid disease, ulcerative colitis, pernicious anemia, etc).1 PCH occurs much more commonly in young children with infections (where a cold temperature is not involved in vivo). The temperature-dependent chronic primary PCH (usually in adults) is extremely rare. Lab abnormalities noted among all the AIHA in general include anemia, unconjugated hyperbilirubinemia, and elevated Lactate Dehydrogenase (LDH) levels.1 Spherocytosis is often seen in WAIHA.1 Severity of the clinical features and labs depend on the extent and rapidity of onset of the anemia and the ability of bone marrow to compensate for the anemia.1 WAIHA with a Direct Anti-globulin Test (DAT) positive only for C3 is relatively rare.

Case presentation
A 79-year-old woman with a history of dementia was referred to our tertiary care center after she was found to have severe anemia with hemoglobin (Hgb) of 3.6, hyperbilirubinemia, and a positive Coombs test at a small hospital a day previously, where she had presented after being found unresponsive by her family. The patient was transfused 4 units at the initial hospital with appropriate rise in the hemoglobin. However, she was noted to be severely anemic with Hgb of 2.6 g/dL upon presentation to our hospital and so was admitted to the intensive care unit for blood transfusion and close monitoring of vitals and Hgb. The patient was also started on Solumederol 1 mg/kg intravenous (IV) and folic acid 1 mg orally once daily. Her initial LDH was 442 U/L; unconjugated bilirubin was 10 mg/dL. A peripheral blood smear showed spherocytes, polychromasia, and reticulocytosis. A DAT was repeated and was positive for C3 alone and was negative for IgG, IgA, and IgM. A cold agglutinin screen and eluate were negative. Her Hgb improved to 10.2 g/dL after Packed Red Blood Cells (PRBC) transfusion, and she was transferred to the step-down unit. She continued to require PRBC transfusions on an as needed basis for Hgb $\leq 8$ g/dL. After discussion with the patient’s family, the patient was admitted to the palliative care unit with discontinuation of as needed PRBC transfusions and any lab testing. She was, however, continued on 0.5 mg/kg Solumederol IV daily. The patient expired after a few days.

A written consent was obtained from the patient’s daughter for the purpose of using patient information for this study.

Discussion
WAIHA commonly has a DAT positive for IgG with or without C3, IgM, and IgA. However, cases of WAIHA with a DAT positive only for C3, IgM, or IgA have been reported.

Though the exact cause of C3 only WAIHA has not definitively been proved, the following hypotheses have been proposed:10

a. Complement components may get bound to the RBC during adherence of antibody-antigen complexes that later dissociate, leaving the complement still attached to the RBC.
b. When natural antibodies associate with RBC damaged by the in vivo action of microbial enzymes, the complement may also be fixed to the RBC.

c. Complement activated in fluid phase by antigen-antibody complexes unrelated to the RBC may then fix to the RBC.

d. The complement may fix to the RBC by IgM that is present in serologically undetectable quantities.

In general, C3 only WAIHA is a relatively rare entity. Also since C3 alone coated RBC are not cleared efficiently by the macrophages and since such complement coating of the RBC is seen in normal subjects also, theoretically the hemolysis in C3 alone coated WAIHA should be mild. For the same reason, sparse IgG coating of the RBC, not detectable by conventional lab testing, has been speculated as a mechanism for increased hemolysis in the rare cases of C3 alone WAIHA with severe hemolysis. However, different authors have mentioned varying incidences and clinical severity of this disease. For this reason, we sought to perform an analytical literature review of these parameters for this disease. A search of Medline NLM and Google with the terms “C3 only warm autoimmune hemolytic anemia” yielded only one pertinent article. Further pertinent articles were derived through the references of the initial article and articles further down. Some references were also obtained through textbooks of Hematology. Through this method, we obtained a total of 13 references of which 6 mentioned an incidence range for this pathology and 3 studies that commented on the presence and severity of hemolysis due to C3 only WAIHA.

Our review yielded the results presented here.

Incidence
Most of the authors reported an incidence for C3 only WAIHA as being less than 25%. Commonly it seems to have an incidence ranging between 6% and 13%. Self-resolving or responding well to simple conservative measures such as oral steroids, to life threatening anemia requiring multiple blood transfusions and refractory to various conservative therapies including prednisone, IVIG, cyclosporine, azathioprine, and danazol and requiring splenectomy. However, in our study, we did not come across any reports of deaths due to this clinical entity. A study involving 72 patients and comparing coexisting underlying diseases, severity of hemolysis, and response to therapy in patients with DAT positive for IgG versus C3 (either alone or in conjunction with IgG), mentioned that coexisting chronic diseases such as lymphatic neoplasms and connective tissue disorders were more common in patients with C3 positivity than the other groups.

The strength of the DAT has not shown a definite correlation to the occurrence or severity of hemolysis despite multiple studies over many years.

Treatment of C3 only WAIHA is not well-documented given the paucity of these cases. However, in the study mentioned above, the most satisfactory initial response to steroids was noted in patients with complement coating and normal cold agglutinins.

Conclusion
WAIHA with a DAT positive for C3 only is relatively rare with an incidence ranging between 6% and 13% and can have a clinical picture ranging from mild to severe anemia. In general, steroids should be used as a first-line therapy in these cases.

Author Contributions
Conceived and designed the experiments: AP. Analyzed the data: AP. Wrote the first draft of the manuscript: AP. Contributed to the writing of the manuscript: AP, FK, MC. Jointly developed the structure and arguments for the paper: AP, FK. Made critical revisions and approved final version: AP, FK, MC. All authors reviewed and approved of the final manuscript.

Funding
Author(s) disclose no funding sources.

Competing Interests
Author(s) disclose no potential conflicts of interest.
Disclosures and Ethics
As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants (if applicable), and that permission has been obtained for reproduction of any copyrighted material. This article was subject to blind, independent, expert peer review. The reviewers reported no competing interests.

References
1. Hoffman R, Benz E Jr, Shattil S, et al. Hematology: Basic Principles and Practice. London, England: Churchill Livingstone; 2009:645–57.
2. Lodi G, Resca D, Reverberi R. Fatal cold agglutinin-induced haemolytic anaemia: a case report. J Med Case Reports. 2010;4:252.
3. Stefanizzi C, Breccia M, Santopietro M, et al. Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient. Int J Hematol. 2009;89(5):720–1.
4. Dhouib N, Guedhami H, Mellouli F, et al. Mycoplasma pneumoniae associated with severe autoimmune hemolytic anemia in a child with homozygous beta-thalassemia. Tunis Med. 2011;89(7):652–3.
5. Patel M, Durao H, Govender Y. Paroxysmal cold haemoglobinuria coexisting with cold agglutinins in a patient with syphilis resulting in peripheral gangrene: a case report. East Afr Med J. 1993;70(8):526–7.
6. Yagasaki H, Kato M, Shimizu N, Shichino H, Chin M, Magishima H. Autoimmune hemolytic anemia and autoimmune neutropenia in a child with erythroblastopenia of childhood (TEC) caused by human herpesvirus-6 (HHV-6). Ann Hematol. 2011;90(7):851–2.
7. Arai A, Imadome K, Fujiwara S, Miura O. Autoimmune hemolytic anemia accompanied by reactivation of an Epstein-Barr virus infection with suppressed CTL response to EBV-infected cells in an elderly man. Intern Med. 2010;49(4):325–9.
8. Rheingold SR, Burnham JM, Rutstein R, Mann CS. HIV infection presenting as severe autoimmune hemolytic anemia with disseminated intravascular coagulation in an infant. J Pediatr Hematol Oncol. 2004;26(1):9–12.
9. Khawaja S, Abdul Muqtadir K, Taj Y. Warm autoimmune haemolytic anaemia and autoimmune hepatitis in an asymptomatic carrier of hepatitis B virus. J Pak Med Assoc. 2011;61(5):512–5.
10. Dacie JV, Worledge SM. Auto-immune haemolytic anemias. Prog Hematol. 1969;6:82–120.
11. Petz LD, Garratty G. Acquired Immune Hemolytic Anemias, 2nd edition. New York, NY: Churchill Livingstone; 2004.
12. Chaplin H, Nasongkla M, Monroe MC. Quantitation of red blood cell-bound C3d in normal subjects and random hospitalized patients. Br J Haematol. 1981;48(1):69–78.
13. Chaudhary R, Das SS, Gupta R, Khetan D. Application of flow cytometry in detection of red-cell-bound IgG in Coombs-negative AIHA. Hematology. 2006;11(4):295–300.
14. Shvidel L, Shtalrid M, Duek A, Haran M, Berrebi A, Sigler E. Direct antiglobulin test reactive with complement only in warm type autoimmune hemolytic anemia. Int J Lab Hematol. 2008;30(6):494–8.
15. Domen RE. Warm red blood cell autoantibodies and the direct antiglobulin test revisited. Am J Clin Pathol. 2004;122(5):673–4.
16. Worledge SM. The interpretation of a positive direct antiglobulin test. Br J Haematol. 1978;39(2):157–62.
17. Eyster ME, Jenkins DE Jr. Erythrocyte coating substances in patients with positive direct antiglobulin reactions. Correlation of gamma-G globulin and complement coating with underlying diseases, overt hemolysis and response to therapy. Am J Med. 1969;46(3):360–71.